340268-75-9

Basic information

• Product Name: 3-ALLYL-2-FLUORO-4-IODO-PYRIDINE
• Synonyms: 3-ALLYL-2-FLUORO-4-IODO-PYRIDINE
• CAS NO: 340268-75-9
• Molecular Formula: C8H7FIN
• Molecular Weight: 263.05
• Mol File: 340268-75-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 275.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.715±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -1.70±0.18(Predicted)
• CAS DataBase Reference: 3-ALLYL-2-FLUORO-4-IODO-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ALLYL-2-FLUORO-4-IODO-PYRIDINE(340268-75-9)
• EPA Substance Registry System: 3-ALLYL-2-FLUORO-4-IODO-PYRIDINE(340268-75-9)

Safety Data

• Hazardous Substances Data: 340268-75-9(Hazardous Substances Data)

Usage

General Description

3-ALLYL-2-FLUORO-4-IODO-PYRIDINE is a chemical compound with the molecular formula C8H7FIN. It is a heterocyclic compound with a pyridine ring substituted with allyl, fluorine, and iodine functional groups. This chemical is commonly used as a building block in organic synthesis and pharmaceutical research. It has been studied for its potential applications in the development of new drugs and agrochemicals. The compound's unique structure and properties make it a valuable tool for creating novel molecules with a range of biological activities. However, due to its potentially hazardous nature, proper handling and safety precautions should be followed when working with 3-ALLYL-2-FLUORO-4-IODO-PYRIDINE.

Upstream product

• 113975-22-7 2-fluoro-3-iodopyridine 
• 106-95-6 allyl bromide 
• 372-48-5 2-fluoropyridine 

Relevant articles and documents

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula (I) or pharmaceutically acceptable salt thereof wherein ring A represents group A-I, A-II or A-III. Al represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A2 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A3 represents -C(R4c)(R4c)-, -C(R4c)= or -0-; A4 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A5 represents -C(R4a)(R4a)-, -C(R4a)= -N(R4b)-, -N= -O- or -S-; A6 represents -C(R4c)(R4c)- or -C(R4c)=; A7 represents -C(R4a)(R4a)-, -C(R4a)= -N= -O- or -S-; A8 represents -C(R4a)(R4a)-, -N(R4b)-, -O- or -S-; A9 represents -C(R4c)(R4c)- or -0-; A10 represents -C(R4c)(R4c)- or -0-; A11 represents -C(R4c)(R4c)- or -0-; A12 represents -C(R4a)(R4a)-, -O- or -S-; wherein group A-I, group A-II and group A-III de not contain adjacent oxygen atoms, adjacent oxygen and sulfur atoms or adjacent oxygen and nitrogen atoms or a moiety selected from the group consisting of N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S, wherein in each case the carbon atom in the N-C-N, N-C-S, S-C-S, O-C-N, O-C-O and O-C-S moiety is saturated; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a, R4b and R4c are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.